Could a multiple sclerosis drug help people with a rare nerve disease walk faster?
NCT ID NCT02868567
First seen Sep 30, 2025 · Last updated May 08, 2026 · Updated 31 times
Summary
This early-stage trial tests whether dalfampridine, a drug used for walking problems in multiple sclerosis, can safely improve walking speed in 35 adults with primary lateral sclerosis or a related upper motor neuron condition. Participants take the drug for 18 weeks and have their walking speed measured regularly. The goal is to see if the drug provides consistent improvement in walking.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MOTOR NEURON DISEASE, UPPER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mass General Hospital
Boston, Massachusetts, 02114, United States
-
Shara Holzberg
New York, New York, 10021, United States
-
University of Florida Gainsville
Gainesville, Florida, 32607, United States
Conditions
Explore the condition pages connected to this study.